Amphotericin formulations, indicated for invasive fungal infections (IFI s), vary in
effectiveness, safety and costs. In Brazil, only the conventional formulation is provided by the …

Objective: A systematic review was performed to compare the effectiveness and tolerability
of lipid-based amphotericin B (AmB) formulations and conventional AmB in the treatment of …

Abstract Background Liposomal amphotericin B (L-AMB) and amphotericin B lipid complex
(ABLC) are both indicated for treating invasive fungal infections (IFIs) caused by Aspergillus …

Background: Potential differences in toxicity, potency and acquisition price among the
liposomal amphotericin B formulations makes it unclear which agent is less costly when total …

Invasive fungal infections, an important cause of mortality, are primarily treated using
amphotericin B, which is available in different formulations, both conventional and lipid …

Introduced in the late 1950s, polyenes represent the oldest family of antifungal drugs. The
discovery of amphotericin B and its therapeutic uses is considered one of the most important …

Invasive fungal infections (IFIs) are a major concern within healthcare systems. This
pharmacoeconomic study evaluated the use of caspofungin (CAS) versus liposomal …

Amphotericin B - StatPearls - NCBI Bookshelf US flag An official website of the United States
government Here's how you know NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Purpose: Patients with invasive fungal infections are often treated initially with conventional
amphotericin B deoxycholate (CAB), followed by a switch to lipid-based formulations of …

The management of superficial fungal infections differs significantly from the management of
systemic fungal infections. Most superficial infections are treated with topical antifungal …